"Gene expression signatures have shown promising both as prognostic as well as predictive tools in primary breast cancer, but they are not routinely used in clinical practice. Several explanatory reasons have been pinpointed, such as lack of statistical confidence, diversity in operational definitions, inclusion of unselected breast cancer populations, as well as the former lack of prospective biological sample collection in older cancer trials." Read the complete ESMO journal club article here.
Study mentioned: Loi S, et al. Prognostic and Predictive Value of Tumor-Infiltrating Lymphocytes in a Phase III Randomized Adjuvant Breast Cancer Trial in Node-Positive Breast Cancer Comparing the Addition of Docetaxel to Doxorubicin With Doxorubicin-Based Chemotherapy: BIG 02-98. J Clin Oncol. 2013 Mar 1;31(7):860-7. PMID: 23341518
No comments:
Post a Comment